Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $27.4250 (0.68%) ($27.0800 - $28.2500) on Thu. Oct. 22, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.75% (three month average) | RSI | 60 | Latest Price | $27.4250(0.68%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -1.8% a day on average for past five trading days. | Weekly Trend | TGTX declines -0.6% a week on average for past two weeks. | Market Behavior | Value stock rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(64%) ARKG(59%) ARKK(56%) IWO(56%) IBB(55%) | Factors Impacting TGTX price | TGTX will decline at least -1.875% in a week (0% probabilities). VIXM(-37%) VXX(-33%) UUP(-18%) IGOV(-3%) TBT(-2%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.875% (StdDev 3.75%) | Hourly BBV | -1.1 () | Intraday Trend | 0% | | | |
|
Inflection Point | Yes | Resistance Level | $28.49 | 5 Day Moving Average | $28.6(-4.11%) | 10 Day Moving Average | $29.42(-6.78%) | 20 Day Moving Average | $28.49(-3.74%) | To recent high | -11.9% | To recent low | 48.4% | Market Cap | $3.473b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |